Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
1,121 results
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Daclizumab [BOOK]
    National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • Daclizumab is a humanized monoclonal antibody to CD25, the alpha subunit of the IL2 receptor on T lymphocytes, which was used in the past to treat and prevent acute cellular rejection after solid organ transplantation and is currently approved as a second line therapy of refactory relapsing multiple sclerosis. Daclizumab has been linked to occasional mild-to-moderate serum enzyme elevations durin…
  • Rash developing after cessation of Daclizumab for relapsing remitting MS; a case series. [Journal Article]
    Mult Scler Relat Disord 2019; 35:239-240Lockhart A, Kirby B, McGuigan C
  • Daclizumab, a monoclonal antibody directed against CD25, a subunit of the high-affinity IL-2 receptor, was licensed as a disease modifying therapy (DMT) for relapsing remitting multiple sclerosis in 2017. Interference with IL-2 signalling is hypothesised to modulate T cell function. For example it results in a preferential shift of innate lymphoid cell (ILC) into CD56bright natural killer cells a…
New Search Next